Mylan N V (MYL) Shareholder Greenlight Capital INC Cut Its Holding

Mylan N.V. (NASDAQ:MYL) LogoInvestors sentiment increased to 2 in Q2 2018. Its up 1.00, from 1 in 2018Q1. It improved, as 2 investors sold MYL shares while 0 reduced holdings. 3 funds opened positions while 1 raised stakes. 356,551 shares or 87.07% more from 190,596 shares in 2018Q1 were reported. Gemmer Asset Management Limited Liability Corp, a California-based fund reported 12 shares. Whittier Com owns 0.37% invested in Mylan N.V. (NASDAQ:MYL) for 142,248 shares. Nevada-based Whittier Tru Of Nevada has invested 0.19% in Mylan N.V. (NASDAQ:MYL). Gulf Intll Natl Bank (Uk) Limited has 0.08% invested in Mylan N.V. (NASDAQ:MYL) for 166,890 shares. Vantage Investment Advsrs Ltd Company invested in 337 shares.

Greenlight Capital Inc decreased its stake in Mylan N V (MYL) by 10.36% based on its latest 2018Q2 regulatory filing with the SEC. Greenlight Capital Inc sold 793,000 shares as the company’s stock declined 9.50% while stock markets rallied. The hedge fund held 6.86M shares of the major pharmaceuticals company at the end of 2018Q2, valued at $247.89M, down from 7.65M at the end of the previous reported quarter. Greenlight Capital Inc who had been investing in Mylan N V for a number of months, seems to be less bullish one the $15.75B market cap company. The stock decreased 4.05% or $1.29 during the last trading session, reaching $30.55. About 5.85M shares traded or 17.07% up from the average. Mylan N.V. (NASDAQ:MYL) has risen 12.23% since December 8, 2017 and is uptrending. It has underperformed by 3.39% the S&P500.

Analysts await Mylan N.V. (NASDAQ:MYL) to report earnings on February, 27. They expect $1.38 earnings per share, down 3.50 % or $0.05 from last year’s $1.43 per share. MYL’s profit will be $711.59M for 5.53 P/E if the $1.38 EPS becomes a reality. After $1.25 actual earnings per share reported by Mylan N.V. for the previous quarter, Wall Street now forecasts 10.40 % EPS growth.

More notable recent Mylan N.V. (NASDAQ:MYL) news were published by: which released: “Mylan (MYL) Down 9.5% Since Last Earnings Report: Can It Rebound? – Nasdaq” on December 05, 2018, also with their article: “Mylan Expands Recall of Valsartan to All Unexpired Lots – Nasdaq” published on December 05, 2018, published: “Market Trends Toward New Normal in Hasbro, Spark Energy, QUALCOMM, Green Brick Partners, Mylan NV, and Magellan Health — Emerging Consolidated Expectations, Analyst Ratings – Nasdaq” on December 06, 2018. More interesting news about Mylan N.V. (NASDAQ:MYL) were released by: and their article: “Mylan lower after FDA warning – Seeking Alpha” published on November 20, 2018 as well as‘s news article titled: “Market Close Report: NASDAQ Composite index closes at 7,188.26 up 29.83 points – Nasdaq” with publication date: December 06, 2018.

Mylan N.V. (NASDAQ:MYL) Ratings Coverage

Among 7 analysts covering Mylan (NASDAQ:MYL), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Mylan had 10 analyst reports since August 9, 2018 according to SRatingsIntel. Citigroup maintained the shares of MYL in report on Thursday, August 9 with “Buy” rating. The rating was maintained by Morgan Stanley with “Equal-Weight” on Tuesday, November 6. The stock of Mylan N.V. (NASDAQ:MYL) has “Neutral” rating given on Friday, October 5 by Mizuho. The stock of Mylan N.V. (NASDAQ:MYL) has “Buy” rating given on Tuesday, November 6 by Citigroup. The firm earned “Buy” rating on Tuesday, November 6 by Bank of America. The firm earned “Equal-Weight” rating on Tuesday, October 9 by Morgan Stanley. The company was downgraded on Thursday, August 9 by Raymond James. On Monday, August 13 the stock rating was upgraded by RBC Capital Markets to “Outperform”. The stock has “Buy” rating by Argus Research on Thursday, November 15. RBC Capital Markets maintained Mylan N.V. (NASDAQ:MYL) rating on Tuesday, November 6. RBC Capital Markets has “Outperform” rating and $50 target.

Mylan N.V. (NASDAQ:MYL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.